
New Research Shows Having an Inflammatory Side Effect During Monoclonal Antibody Treatments for Lung Cancer is Linked to Improved Survival Rates
For those with advanced non-small cell lung cancer (NSCLC), having an immune or inflammatory side effect, called an immune-related adverse event (irAE) from a monoclonal antibody treatment correlates...